VistaGen Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VistaGen Therapeutics, Inc. on June 27, 2013. The filing reports the entry into a material definitive agreement involving a second amendment to a Securities Purchase Agreement originally dated April 8, 2013. The agreement involves the Company, Autilion AG (Switzerland), and Bergamo Acquisition Corp. PTE LTD (Singapore).
Key Financial Metrics and Transaction Details
The filing details a multi-stage equity financing arrangement. On the date of the amendment (June 27, 2013), the Company issued 50,000 shares of common stock to Autilion at $0.50 per share, generating immediate proceeds of $25,000. The total potential investment under the amended schedule is $36,000,000, contingent on future closing dates.
| Investment Date | Total Amount | Total Shares |
|---|---|---|
| On date of Amendment (June 27, 2013) | $25,000 | 50,000 |
| On or before July 11, 2013 | $475,000 | 950,000 |
| On or before July 27, 2013 | $9,500,000 | 19,000,000 |
| On or before August 30, 2013 | $10,000,000 | 20,000,000 |
| On or before September 30, 2013 | $16,000,000 | 32,000,000 |
The filing does not provide data on revenue, operating profit, cash flow, margins, or existing debt levels. Proceeds from the sale are designated for general corporate purposes.
Material Changes and Structural Adjustments
Key changes to the original agreement include:
- Termination of the Assignment and Assumption Agreement previously entered into on April 12, 2013.
- Autilion AG assumed all rights and obligations of the Purchaser under the Securities Purchase Agreement.
- Amendment of scheduled investment dates to establish a first closing on the amendment date and a final closing deadline of September 30, 2013.
Outlook, Risks, and Unusual Items
The Company issued a press release on June 28, 2013, to update stakeholders on the financing status. The shares were sold in a transaction exempt from registration under Section 4(2) of the Securities Act and Rule 506 of Regulation D, with Autilion represented as an accredited investor. The filing does not contain specific forward-looking guidance, risk factors, or management commentary beyond the transaction mechanics.
Investor Verification Checklist
- Verify the execution of the Second Amendment to the Securities Purchase Agreement (Exhibit 10.1).
- Confirm the receipt of the initial $25,000 proceeds and the issuance of 50,000 shares.
- Monitor the Company's ability to meet the subsequent investment milestones scheduled between July and September 2013.
- Review the full text of the Securities Purchase Agreement to understand conditions precedent for future closings.